All In MedTech

Device Trial Radar · NCT07278986

CYTALUX for Intraoperative Imaging of Patients With Endometrial Cancer

Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Imaging of Patients With Endometrial Cancer Planned for Surgery

Last checked: Nov 19, 2026Latest source record: Dec 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Oct 18, 2025

Primary completion

Oct 2027

Study completion Feb 2029

Sponsor

Lead sponsor
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 12, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The research study is being done to assess the safety and ability of an investigational drug called CYTALUX (pafolacianine) and a special camera system for the detection of cancer in patients undergoing surgical resection for endometrial cancer.

Conditions

  • Endometrial Cancer
  • Near Infrared Fluorescence Imaging
  • CYTALUX (Pafolacianine) Injection
  • Planned Diagnostic Laparoscopies

Interventions

  • CYTALUX™ (pafolacianine)Drug

    CYTALUX™ (pafolacianine) injection and standard care laparoscopic evaluation of disease. Intraoperative imaging with Cytalux will be performed for assessment of disease detection in patients who are being evaluated to undergo surgery for endometrial cancer. Any tissues removed as part of standard of care will undergo assessment with NIR light imaging prior to and after resection. This will be then compared to gold standard histologic confirmation by pathology.

  • 1788 4K Camera System with Advanced Imaging ModalityDevice

    Combination Product

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointTime frame: 2 months after surgery

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Abramson Cancer Center at Penn Medicine

    Philadelphia, Pennsylvania · Recruiting

  • University of Pennsylvania Gynecologic Oncology Department

    Philadelphia, Pennsylvania · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.